Pipeline
Sumitomo Pharma America doses first patient in RP cell therapy trial
Phase 1/2a trial evaluating DSP-3077 as a regenerative cell therapy is estimated to complete in October 2028.
Research
Does vitamin supplementation help DED?
Evidence suggests certain vitamins may show promise, but researchers say the data is not strong enough yet to support routine supplementation.
Events
International Keratoconus Academy to host 4th annual symposium
Kicking off this December, the one-day event offers CE , CME , and faculty-led sessions spotlighting interventional keratoconus care and
Products
FDA expands TearCare System indication for MG function improvement
Label update makes the 510(k)-cleared device the first and only for this indication; includes an optional debridement.
Research
FGFR inhibitor cancer drugs linked to dry eye, corneal damage
Real-world analysis of the FDA's adverse event database flags ocular safety signals that extend past what clinical trials and drug labels report.
Business
Eyebot partners with QUAY to install in-store vision kiosks
Self-serve vision testing system is now available at select QUAY retail locations for consumers receiving updated prescriptions.
Products
FDA clears ZEISS Clinic 360 ophthalmic analytics dashboard
All-in-one, cloud / browser-based software solution integrates into ophthalmic workflows with flexible and scalable data management for patient care.
Research
Study finds sex differences in uveitis risk among GLP-1 users
Women on long-term GLP-1 receptor agonist therapy showed significantly higher uveitis risk than men.
Pipeline
EyePoint’s DURAVYU delivers mixed endpoint results in first phase 3 wet AMD trial
Primary endpoint not achieved in full dataset while ad-hoc analysis excluding asymmetric cohort demonstrated non-inferiority to on-label aflibercept.
Research
Eyedaptic AI smart glasses deliver 5.7-line acuity gain in AMD
Study demonstrates significant and immediate VA improvements in patients with advanced retinal disease.
Products
FDA recalls over 39K bottles of CLEAR EYES Maximum Itchy Relief drops
Federal agency added Class II classification last week after identifying the potential risk for sterility issues with the OTC product.
Research
New research confirms association of OSA with glaucoma
Real-world cohort study indicates patients with obstructive sleep apnea may have a higher long-term risk of developing glaucoma.
Business
Omega Ophthalmics raises $7M to advance injectable IOL platform
Financing to support clinical development and future studies of a novel implant for cataract surgery; FDA-pre submission meeting is now scheduled.
Research
Rosacea may double risk for DR progression
Patients with rosacea and early-stage DR had more than twice the risk of progressing to proliferative disease—and a higher need for retinal intervention over 5 years.
Business
WaveFront Dynamics integrates B+L, Wave Eye Care scleral lenses
Offers ECPs expanded access to advanced wavefront-guided diagnostics with proprietary optic design services—plus new scleral lens offerings.
Research
Side sleepers face higher risk of uneven glaucoma
Reduced ONH blood flow in the dependent eye during side sleeping may help explain asymmetric damage in patients with obstructive sleep apnea.
Research
BostonSight's PROSE treatment linked to Mackie stage, VA gains in NK
Retrospective observational analysis supports the FDA-cleared scleral lens device as an effective tool in treating neurotrophic keratitis.
Pipeline
Oculis buys out privosegtor’s global rights from Accure
Updated deal includes total purchase of development and commercial rights as company advances its phase 3 PIONEER program for ON.
Pipeline
FDA accepts Belite's tinlarebant NDA for Stargardt
Federal agency also grants priority review for the once-daily oral therapeutic, establishing a PDUFA target action date for Feb. 12, 2027.
Pipeline